Key words
exercise therapy - rehabilitation - sex characteristics - COVID-19 - respiratory function tests - six-minute walk test
Introduction
Since the corona virus disease 2019 (COVID-19) was declared a pandemic in March 2020,
healthcare providers have been globally challenged to manage disease spreading and
maintain instant and long-term medical treatment for all affected individuals [1]. As the pandemic progresses, COVID-19-related sex
disparities have been observed. The risk of a severe progression of COVID-19 has
consistently been found two times greater for men than for women worldwide, measured
by the number of deaths, hospitalizations, intensive care unit stays and intubations
for mechanical ventilation [2]
[3]
[4]. Especially men between the ages of
65 and 85 have dominated the prevalence of COVID-19-related deaths [5], probably associated with chronic metabolic disease,
such as obesity, type 2 diabetes and hypertension [6],
or cardiovascular disease tending to affect men more frequently than women [6]
[7]
[8]. Potential reasons range from biological factors,
including stronger female immune response to viral infections and protective
properties of estrogen, to social factors e.g., higher alcohol consumption and
enhanced smoking behavior in men [9]
[10]
[11].
A SARS-CoV-2 infection specifically affects the respiratory system and symptoms have
been shown to be manifested six months to one year after hospital discharge [12]
[13]. Patients,
predominantly males, who were seriously ill during their hospital stay had more
severely impaired lung function capacities whereas lung diffusion impairment and
fatigue or muscle weakness were symptoms mainly observed in women six months after
their hospital discharge [12]
[13]. However, these patients may not have undergone inpatient
rehabilitation following their acute hospital stay. Evidently, pulmonary
rehabilitation has been promoted as a key treatment component after acute COVID-19
illness and applied successfully including standardized exercise therapy
interventions connected to a multidisciplinary approach [14]
[15]. This has been shown in improved
lung function parameters and functional exercise capacity of post-acute COVID-19
patients after three to five weeks [16]
[17]. Especially respiratory exercise has led to a
significant improvement in lung function and physical performance in elderly
patients [18]. These findings emphasize the
effectiveness of pulmonary rehabilitation reducing recovery time after burden of
COVID-19. So far however, it has not been investigated, if standardized pulmonary
rehabilitation is equally efficacious in males and females in the post-acute stage
after a COVID-19 infection. Therefore, based on sex disparities in former
hospitalized COVID-19 patients [19]
[20], we aimed to analyze the outcomes of standardized
pulmonary rehabilitation in post-acute COVID-19 patients with respect to
sex-specific differences. The purpose of the study is to initiate a discourse with
other researchers evaluating the relevance of sex-specific approaches in
standardized rehabilitation treatments of COVID-19 patients.
Materials and Methods
Design and Data Source
The retrospective case series contains data from post-acute COVID-19 patients who
were admitted to a standardized three-week pulmonary rehabilitation program at
the Clinic for Rehabilitation in Münster, Austria. They were admitted
between the 1st of March 2020 and 31st of May 2021, due to
a laboratory confirmed SARS-CoV-2 infection prior to rehabilitation, according
to the definition of the Austrian Federal Ministry of Social Affairs &
Health Care. Initially, data of all eligible patients who underwent
rehabilitation in this time frame were screened by a physician. Before data
evaluation, data were pseudonymized and then extracted from the clinic
information system (MP2 IT-Solutions, Austria). Data pseudonymization and
extraction were carried out by one physician and one research assistant. Data
privacy was guaranteed by an in-house data protection agreement made by a
commissioner for data protection. Steps of the retrospective data analyses are
shown in [Figure 1]. The research ethics
committee of the Medical University of Innsbruck approved the study protocol
(1066/2021) and the study was registered at the German Clinical Trials
Register (ID: DRKS00026936).
Fig. 1 Flow diagram of data extraction and processing.
Characteristics of Patients’ Data
Records from post-acute COVID-19 patients with the principal diagnosis ICD U.07.1
(COVID-19) were analyzed. Anthropometric data as well as secondary diagnoses
which were present before the COVID-19 infection were included in the analyses.
Secondary diagnoses included cardiovascular and cerebrovascular diseases,
chronic kidney diseases, obstructive pulmonary disease (COPD), bronchial asthma,
as well as diabetes and hypertension. These diagnoses were documented by the
treating physician. Diabetes mellitus was defined by an elevated hemoglobin (Hb)
A1c value of≥6,5% (≥48 mmol/mol) or prescribed
anti-diabetic medication [21]. Hypertension was
defined by>130/80 mmHg or prescribed antihypertensive
medication according to the International Society of Hypertension Guidelines
[22]. Patients were admitted to pulmonary
rehabilitation as soon as they were physically stable without the need of
continuous supervision, invasive or non-invasive ventilation. They could be
admitted after being tested negative twice by real-time polymerase chain
reaction via swab. If patients terminated their stay before completing the
three-week program or if admission and discharge measurements were incomplete,
their data were excluded from analyses (see [Figure
1]).
After inclusion, patient’s data were categorized according to
Huang’s COVID-19 severity scales (Huang, 2021):
Scale 1: not admitted to hospital before rehabilitation stay with resumption of
normal activities
Scale 2: not admitted to hospital before rehabilitation stay, but unable to
resume normal activities
Scale 3: admitted to hospital before rehabilitation stay and not requiring
supplemental oxygen
Scale 4: admitted to hospital before rehabilitation stay, but requiring
supplemental oxygen
Scale 5: admitted to hospital before rehabilitation stay requiring high flow
nasal cannula (HFNC), non-invasive mechanical ventilation (NIV) or both
Scale 6: admitted to hospital before rehabilitation stay requiring extracorporeal
membrane oxygenation, invasive mechanical ventilation (IMV) or both
Scale 7: death (not applicable)
Included Measurement Data
After their admission to rehabilitation, patients were assessed following a
standardized clinical routine. As part of this clinical routine, the Six-Minute
Walk Test (6MWT) and pulmonary function testing were carried out at the
beginning and at the end of the three-week rehabilitation stay. The 6MWT is a
well-documented standardized assessment used to assess walking endurance and
functional exercise capacity and has been used to assess the response to medical
interventions in diverse patient groups [23]. It
was executed by an experienced and well-instructed physiotherapy staff member
according to the guidelines of the American Thoracic Society (ATS) [24]. 6MWT outcome values were compared to 6MWT
reference values for recovered healthy adults according to Enright et al., [25]. The corresponding reference values for each
participant were calculated according to reference equations for men:
6MWD=(7.57 x height(cm) – (5.02 x
age(years)) – (1.76 x weight(kg)) –
309 m; for women: 6MWD=(2.11 x height(cm)) –
2.29 x weight(kg)) – (5.78 x
age(years))+667 m [25].
The difference in pre and post measurements of the 6MWT were compared to the
minimal clinically important difference across multiple patient groups [26] and to reference values for patients suffering
from acute respiratory distress syndrome or having survived acute respiratory
distress syndrome [27]. After the 6MWT, maximal
inspiratory capacity (ICmax) was measured using a manometer connected
to a PEP-RMT-System (Positive Expiratory Pressure- Respiratory Muscle Training-
System) (Mediplast, Malmö, Sweden). Further pulmonary functions were
tested using body-plethysmography (Master Screen Body, Traeger GmbH, Hoechberg,
Germany). Measurements were carried out by an experienced physician according to
recent updated guidelines by the ATS [28] and the
European Respiratory Society (ERS) [29]
[30].
Primary outcomes included the 6MWT, ICmax measured by the
PEP-RMT-System as well as Forced Vital Capacity (FVC) and Forced Expiratory
Volume in the first second (FEV1) assessed by body-plethysmography.
FVC and FEV1 were compared to calculated reference values of
body-plethysmography. Secondary outcomes included the number and type of
exercise therapy sessions throughout the patients’ rehabilitation
visit.
Exercise Therapy Interventions
All post-acute COVID-19 patients admitted to pulmonary rehabilitation followed a
standardized program with a duration of at least three weeks, including exercise
therapy sessions on 5–6 weekdays. Each week, patients participated in a
maximum of 3 exercise therapy sessions per day (Monday to Friday). The exercise
therapy sessions consisted of individual respiratory muscle training, pulmonary
group exercises, individual strength exercises (3 to 5 exercises for large
muscle groups in three series of 8 to 12 repetitions per exercise with or
without weight machines), individual endurance training (cycling, treadmill, in
and outdoor walking) and relaxation group exercises. Intensities and intervals
of endurance training were based on the results of the 6MWT performance. For
respiratory muscle training, a hand-held resistance device was used
(PEP-RMT-System, Mediplast, Malmö, Sweden) for 3 sets of 10 breaths each
and a 1-min rest between sets. Each exercise session lasted for
30–45 min and was supervised by a exercise therapist or a
physiotherapist. The amount and type of the group exercise therapy sessions and
the amount of individual physiotherapy sessions were determined by the
physicians in charge.
Statistical Analyses
Descriptive characteristics and secondary diagnoses of males and females were
presented as mean with standard deviation or percentages. Spearman’s
rank correlations between COVID-19 severity and secondary diagnoses were
calculated, as COVID-19 severity was categorized by the ordinally scaled
COVID-19 Severity Scale (Huang et al., 2021). Spearman’s rank
correlations were also calculated between the number of respiratory muscle
training sessions and lung function parameters (FEV1, FVC and
ICmax) as well as the 6MWT. For the comparison of functional
exercise capacity (6MWT) and lung function parameters (FEV1, FVC and
ICmax) by sex, Welch-ANOVA was used, as results of
Levene's test suggested significant heteroscedasticity regarding the
investigated parameters (p>0.05). When comparing post-treatment 6MWT,
FEV1 and FCV to corresponding reference values, paired t-tests
were used.
Results
In total, 233 previously confirmed COVID-19 cases were included in the analyses i.e.,
94 (40.4%) females and 139 (59.6%) males. The mean number of
rehabilitation days was 21.51 (±2.22) for females and 21.86 (±3.75)
for males with no significant differences between groups. Baseline characteristics
such as body mass index (BMI), smoking status or comorbidities also did not differ
significantly between groups as seen in [Table 1].
Considering the previous COVID-19 infection, females were significantly less
affected by COVID-19 severity according to Huang’s severity stages than
males (p=0.004). COVID-19 severity and the comorbidity of bronchial asthma
exhibited a weak negative correlation (r=–0.16; p<0.05),
while cerebrovascular diseases showed a weak positive correlation with COVID-19
severity (r=0.16; p<0.05). No further significant correlations
between secondary diagnoses and COVID-19 severity were found (all p>0.05).
Furthermore, neither smoking status nor overweight or obesity
(BMI≥25 kg/m2) was significantly associated
with a more severe COVID-19 history (p>0.05). Details about the COVID-19
severity, patients’ characteristics and secondary diagnoses are shown in
[Table 1].
Table 1 Comparison of descriptive measures of patients by
sex
Category
|
Females (n=94)
|
Males (n=139)
|
T(df)
|
p
|
|
M
|
SD
|
M
|
SD
|
|
|
Age (years)
|
61.50
|
12.81
|
61.69
|
11.55
|
−0.12(231)
|
NS
|
Weight difference (kg)
|
|
|
|
−0.58
|
1.49
|
−0.36
|
BMIPre (kg/m2)
|
29.10
|
7.04
|
28.47
|
5.09
|
0.73(153.77)
|
NS
|
BMIPost (kg/m2)
|
28.93
|
6.91
|
28.39
|
5.00
|
0.65(152.01)
|
NS
|
|
Females (n=94)
|
Males (n=139)
|
χ2(df)
|
p
|
|
M
|
%
|
M
|
%
|
|
Smoking status
|
|
|
|
|
2.61(2)
|
NS
|
Non-smoker
|
51
|
54.26
|
63
|
45.32
|
|
|
Current smoker
|
2
|
2.13
|
1
|
0.72
|
|
|
Former smoker
|
40
|
42.55
|
71
|
51.08
|
|
|
Comorbidities
|
|
|
|
|
|
|
Hypertension
|
37
|
39.4
|
72
|
51.8
|
3.48(1)
|
NS
|
Diabetes
|
38
|
40.4
|
65
|
46.76
|
0.91(1)
|
NS
|
Cardiovascular disease
|
35
|
37.2
|
55
|
39.57
|
0.13(1)
|
NS
|
Cerebrovascular disease
|
6
|
6.4
|
7
|
5.04
|
0.19(1)
|
NS
|
COPD
|
9
|
9.6
|
9
|
6.47
|
0.76(1)
|
NS
|
Bronchial asthma
|
17
|
18.1
|
17
|
12.23
|
1.54(1)
|
NS
|
Chronic kidney disease
|
7
|
7.4
|
13
|
9.35
|
0.26(1)
|
NS
|
COVID-19 Severity Scale*
|
|
|
|
|
15.63(4)
|
0.004
|
Scale 2
|
35
|
37.2
|
28
|
20.14
|
|
|
Scale 3
|
28
|
29.8
|
30
|
21.58
|
|
|
Scale 4
|
10
|
10.6
|
20
|
14.39
|
|
|
Scale 5
|
9
|
9.6
|
28
|
20.14
|
|
|
Scale 6
|
12
|
12.8
|
33
|
23.74
|
|
|
Notes. BMIPre=Body Mass Index at rehabilitation
entry, BMIPost=Body Mass Index at rehabilitation
discharge; M (SD)=mean±standard deviation;
T(df)=t-distribution with degrees of freedom; NS=level of
significance>0.05; χ2(df)=chi-square
value with degrees of freedom; COPD=Chronic Obstructive Pulmonary
Disease; *defined as Scale 2=not admitted to hospital
before rehabilitation stay, but unable to resume normal activities; Scale
3=admitted to hospital before rehabilitation stay and not requiring
supplemental oxygen; Scale 4=admitted to hospital before
rehabilitation stay but requiring supplemental oxygen; Scale
5=admitted to hospital before rehabilitation stay requiring HFNC,
NIV or both; Scale 6=admitted to hospital before rehabilitation stay
requiring invasive mechanical ventilation.
Exercise Therapy Sessions
Within the 3 weeks of pulmonary rehabilitation, females completed an average of
34.29 and males an average of 35.23 exercise therapy sessions, with no
significant differences between sexes (p=0.284). The different types of
exercise therapy (i.e. strength, endurance and relaxation exercises and
respiratory muscle training) were equally distributed between sexes, except for
a trend (p=0.056) in males receiving more sessions of respiratory muscle
training when compared to females. A detailed description of exericse therapy
sessions is provided in [Table 2]
.
Additionally, females received 6.88 and males 7.42 individual physiotherapy
sessions on average. No significant correlations were found between the number
of respiratory muscle training sessions and lung function parameters
(FEV1, FVC and ICmax) as well as the 6MWT (all
p>0.05).
Table 2 Number of exercise therapy sessions by females and
males
|
|
Female (n=94)
|
Male (n=139)
|
Respiratory muscle exercise*
|
M (SD)
|
6.82 (±2.08)
|
7.39 (±2.31)
|
Pulmonary group exercise
|
M (SD)
|
6.37 (±2.60)
|
6.71 (±2.57)
|
Strength exercise
|
M (SD)
|
6.40 (±2.79)
|
6.18 (±2.77)
|
Endurance exercise
|
M (SD)
|
9.84 (±3.49)
|
10.38 (±2.67)
|
Relaxation exercise
|
M (SD)
|
4.85 (±1.89)
|
4.58 (±2.13)
|
All training therapy sessions
|
M (SD)
|
34.29 (±7.74)
|
35.23 (±5.66)
|
Notes. * T(df)=–1.92(231),
p=0.056; M (SD)=mean±standard deviation
Six-Minute Walk Test
Both males and females showed a statistically significant improvement in walking
distance after the 3 week rehabilitation
(T(232) =–16.67; p<0.001; d=0.48). The
difference was not sex dependent (p>.05; see [Table 3]). When comparing the 6-minute walking distance (6MWD) at
rehabilitation discharge to corresponding reference values for healthy persons
(Enright et al., 1998), males showed significantly reduced walking distances
compared to females (T(231)=–3.04; p<0.01;
d=0.41). In correspondence to that, males exhibited an actual average
distance of 498.08 meters (m) vs. a reference average distance of
573.66 m (p<0.01), as compared to female patients whose actual
and reference [6]MWD values were not significantly
different (average 477.29 m vs. 493.93 m; p=0.259).
Table 3 Sex differences (Welch-ANOVA) in outcome
measures.
Measures
|
Female (n=94)
|
Male (n=139)
|
F
|
df
|
ω2
|
p
|
|
M
|
SD
|
M
|
SD
|
|
|
|
|
|
6MWT
|
|
|
|
|
|
|
|
|
|
Pre
|
405.80
|
134.70
|
435.47
|
153.19
|
2.43
|
1,
|
215.65
|
–
|
0.14
|
Post
|
477.29
|
130.76
|
498.08
|
148.55
|
1.27
|
1,
|
215.53
|
–
|
0.32
|
Difference
|
71.49
|
69.75
|
62.61
|
53.50
|
1.09
|
1,
|
164.21
|
–
|
0.33
|
FVC
|
|
|
|
|
|
|
|
|
|
Pre
|
2.80
|
0.77
|
3.68
|
1.00
|
56.68
|
1,
|
226.52
|
0.24
|
0.00
|
Post
|
2.95
|
0.76
|
3.90
|
0.98
|
69.47
|
1,
|
226.43
|
0.29
|
0.00
|
Difference
|
0.14
|
0.35
|
0.22
|
0.46
|
2.03
|
1,
|
228.15
|
–
|
0.17
|
FEV
1
|
|
|
|
|
|
|
|
|
|
Pre
|
2.29
|
0.66
|
2.98
|
0.81
|
51.47
|
1,
|
223.33
|
0.22
|
0.00
|
Post
|
2.37
|
0.62
|
3.17
|
0.83
|
69.80
|
1,
|
228.26
|
0.30
|
0.00
|
Difference
|
0.09
|
0.25
|
0.19
|
0.39
|
5.86
|
1,
|
230.81
|
0.02
|
0.02
|
FEV
1
/FVC
|
|
|
|
|
|
|
|
|
|
Pre
|
82.42
|
0.04
|
81.72
|
9.57
|
0.25
|
1,
|
180.45
|
–
|
0.62
|
Post
|
80.82
|
0.04
|
81.67
|
10.17
|
0.30
|
1,
|
154.74
|
–
|
0.59
|
Difference
|
1.60
|
0.04
|
0.04
|
13.22
|
1.39
|
1,
|
145.93
|
–
|
0.24
|
IC
max
|
Female (n=94)
|
Male (n=136)
|
|
|
|
|
|
Pre
|
33.09
|
13.78
|
50.06
|
20.69
|
55.75
|
1,
|
227.72
|
0.24
|
0.00
|
Post
|
49.02
|
19.03
|
72.99
|
24.34
|
69.99
|
1,
|
224.48
|
0.30
|
0.00
|
Difference
|
15.94
|
14.07
|
22.93
|
21.44
|
8.93
|
1,
|
227.46
|
0.03
|
0.00
|
Notes. 6MWT=Six-Minute-Walk Test in meters;
FVC=Forced vital capacity in liters;
FEV1=Forced expiratory volume in the first second in
liters; ICmax=maximal inspiration capacity in mbar;
pre=measures at rehabilitation admission; post=measures
at rehabilitation discharge
Lung Function Testing
Both male and female patients improved their maximal inspiration capacity
(ICmax) during the three weeks of rehabilitation (T
(229)=15.972; p<0.001; d=1.05), however, the improvement
was significantly superior in males as compared to females (F
(1,227.46)=8.93; p>0.01; ω2=0.03).
While no sex-related differences were found regarding the ratio of
FEV1/FVC (p>0.05), male patients exhibited higher
pre (F (1,226.52)=56.68, p<0.001;
ω2=0.24) and post treatment FVC (F
(1,226.43)=69.47; p<0.001; ω2=0.29;).
However, no significant sex-interaction was observed (p>0.05).
Similarly, the results suggested higher pre (F (1,223.33)=51.47;
p<0.001; ω2=0.22) as well as post treatment
FEV1 (F (1,228.26)=69.80; p<0.001;
ω2=0.30) in males compared to females. Moreover,
female patients showed a significantly smaller difference regarding the
improvement in FEV1 than males (F (1,230.81)=5.86;
p<0.05; ω2=0.02 see [Figure 2]). The results of primary outcome measures are detailed in
[Table 3].
Fig. 2 Changes in FEV1 values at rehabilitation entry
and discharge in female and male patients. Legend: FEV1
(liter)=forced expiratory volume in the first second;
pre-treatment: measurement before start of rehabilitation;
post-treatment: measurement at the end of rehabilitation
Compared to individual corresponding reference values, patients showed
significantly reduced FVC (pretreatment: T(232)=–11.19;
p<0.001; d=0.73; posttreatment: T(232)=–4.05;
p<0.001; d=0.27) and FEV1 (pretreatment:
T(232)=-10.22; p<0.001; d=0.67; posttreatment:
T(232)=–7.00; p<0.001; d=0.46) before and after
the three-week rehabilitation program.
While there was no sex-related difference in posttreatment FVC (p>0.05),
female patients exhibited significantly lower differences between actual and
corresponding reference values regarding pretreatment FVC
(T(228.51)=5.05; p<0.001; d=0.67) and pre- as well as
posttreatment FEV1 (pretreatment: T(228.85)=4.36;
p<0.001; d=0.58; posttreatment: T(231)=2.83;
p<0.01; d=0.38). Details about FEV1 reference value
and actual value changes are shown in [Figure
3].
Fig. 3 Comparison of actual pre-/post-treatment FEV1
values and reference FEV1 values for female and male
patients. Legend: FEV1 (liter)=forced expiratory
volume in the first second; pre-treatment: measurement before start of
rehabilitation and post-treatment: measurement at the end of
rehabilitation; target values: calculated from body-plethysmography
Discussion
This study highlights sex disparities in positive outcomes of lung function
parameters after a standardized 3-week pulmonary rehabilitation in a cohort of 233
post-acute COVID-19 patients. Male patients showed significantly greater
improvements in specific lung function parameters i.e. FEV1 and
ICmax than female patients. Furthermore, values from female patients
corresponded more closely with FEV1 normative values than male
patients.
These sex disparities could be associated with the clinical representation of the
investigated COVID-19 cohort. Male patients were significantly more affected by
COVID-19 during their acute hospital stay prior to pulmonary rehabilitation than
female patients, matching the results of other studies that have investigated
COVID-19 hospital cohorts [2]
[3]
[31]. As a possible consequence, baseline
FEV1 and FVC values in men were poorer than those of women prior to
their rehabilitation, with respect to individual normative values. As a possible
consequence, specifically respiratory exercise sessions could have been enhanced in
male patients as part of exercise therapy interventions compared to female patients
which might have contributed to their greater improvements. Furthermore,
standardized exercise therapy interventions in pulmonary rehabilitation might have
had a greater effect in men as compared to women, due to a standard exercise
principle: there is a greater likelihood of a pulmonary function improvement during
a training period in the more untrained and the more disease affected people than in
the more trained and less disease affected cohort, respectively [32]. A similar effect could also be observed by others
showing greater improvements in patients with higher hyperglycaemia or hypertension
levels at baseline after lifestyle interventions as compared to those with lower
levels at baseline [33]. Furthermore, skeletal muscle
mass, physical fitness as well as the amount of physical activity could represent
confounding variables which positively influence exercise training outcomes as
recently shown in a SARS-CoV-2-positive study population of athletes [34] In addition, patients with comorbidities such as
chronic obstructive pulmonary disease (COPD) and bronchial asthma are suggested to
lead to reduced values of FEV1 and ICmax. However, in our
study cohort, the same number of women (n=9) and men (n=9) were
affected by these comorbidities, which possibly hampered the evaluation of sex
differences.
Further, morphological differences between men and women need to be considered when
interpreting the greater improvement in FEV1 and ICmax in men.
Smaller lung size and proportionally smaller airways in women, as well as different
size and shapes of the lung and rib cage tend to lead to functional differences. For
example, an expiratory flow limitation and greater cost of breathing has been
observed during exercise in women, including particular activation of inspiratory
muscles [35]
[36]. At a
given minute ventilation women have to perform greater respiratory work due to
smaller airways, which may also induce different patterns of respiratory muscle
activation in order to distribute the ventilation load [37]. Therefore, muscles such as sternocleidomastoid or the scalene
muscles could be activated to a greater extent by women in order to assist the
diaphragm work. This might result in less efficient general activation of
respiratory muscles as well as to a conditioned response to respiratory muscle
exercise [37]
[38].
However, these functional implications of sex differences in respiratory muscle
activation remain to be fully investigated [35].
In this regard, the trend of a greater number of respiratory muscle exercise sessions
in men has to be mentioned. The overall number of exercise therapy sessions did not
differ between sexes however. A reason for this uneven, yet not significantly
different distribution could be the greater need of respiratory muscle exercise in
men, due to their more severe COVID-19 symptoms when compared to women. In inpatient
pulmonary rehabilitation, an individual approach is primarily used, with applying
exercise programs as needed by each patient for their individual physical
improvement [15]
[16].
The significant FEV1 and non-significant FVC improvement only in men
could be related to the previous finding of a significant FEV1 reduction
in patients with cardiorespiratory pathologies; for these diseases, a higher
prevalence has been reported in males compared to females [8]
[39]. However, the present COVID-19
patient male and female cohort were similar with regard to pre-existing
cardiorespiratory pathologies.
The significant improvement in the 6MWT as a performance measure of exercise capacity
in both sexes was in line with Liu et al., and Spielmanns et al., who reported
similar improvements in severe post-COVID-19 patients and elderly patients with
COVID-19 [17]
[18]. The
majority of investigated patients of this study’s cohort exceeded the
threshold of 54 m for a clinically significant change, as well as the newly
proposed 14 to 30.5 m across multiple patient groups [26]
[40]. For patients
suffering from acute respiratory distress syndrome or survivors of acute respiratory
distress syndrome, a minimal clinically important difference (MCID) of 20 to
30 m was proposed [27]. However, when the 6MWD
was compared to corresponding normative values for healthy people [25] at rehabilitation discharge, there was a
discrepancy between male and female patients, with significantly poorer walking
endurance in males. From this could be derived that it is women rather than men who
may be closer to a healthy status of functional exercise capacity after a three-week
pulmonary rehabilitation program.
The effectiveness of a three to six-week standardized pulmonary rehabilitation after
COVID-19 has been shown in previous studies and the number and type of comorbidities
of this study’s COVID-19 patient cohort are in line with others, as well as
the improvement of total values of lung function parameters [17]
[18]
[41]
[42]. Despite the demonstrated
effectiveness, the failure of lung function parameters and functional exercise
capacity reaching normative values at rehabilitation discharge majorly underlines
the necessity of long-lasting pulmonary rehabilitation in former COVID-19 patients.
The usual publicly financed time frame for inpatient pulmonary rehabilitation in
Austria does not exceed five to six weeks [43].
Further gains in lung function and exercise capacity could probably be promoted
through longer pulmonary rehabilitation programs offered in health care
settings.
We acknowledge that the present study has several limitations. First, we cannot
report on the causality of the observed findings due to the observational study
design. Second, caution is advised when claiming an overall improvement in lung
function parameters and functional exercise capacity without an appropriate
non-COVID-19 control group. The main focus of this study is the inter-subject
comparison between sexes. Third, we cannot exclude an impact of additional medical
treatment measures on the outcome of functional exercise capacity and lung function
parameters in regard to the multidisciplinary rehabilitation plan. Fourth, it was
not possible to extract and interpret diffusion capacity of the lungs due to missing
data, associated with the nature of retrospective data collection. Additionally,
baseline characteristics such as diet, alcohol consumption, HbA1c values and current
as well as past physical activity levels limit the description of the study
population. It has been shown that promoting physical activity in COVID-19 patients
is connected to more positive outcomes, therefore the physcial activity behavior
should be regarded when assessing future clinical populations [44]. This study exclusively investigated physical
function of rehabilitated COVID-19 patients whereas psychological aspects such as
quality of life could not be evaluated, which contribute essentially to the recovery
of COVID-19 [45]
[46].
Finally, long-term results of inpatient pulmonary rehabilitation on sex differences
cannot be derived from this data.
In summary, pulmonary rehabilitation programs have shown to be beneficial in the
recovery from COVID-19, however, men appear to benefit more than women, with respect
to particular lung function parameters (FEV1 and ICmax).
Furthermore, women who previously suffered from COVID-19 and subsequently underwent
rehabilitation treatment, seem to have better lung function parameters and
functional exercise capacity than men compared to corresponding reference values.
This knowledge could be of importance when designing pulmonary rehabilitation
programs or when conducting respiratory muscle exercise sessions in a group setting,
where an individual approach to each patient cannot be as guaranteed as in an
one-on-one exercise session. However, further studies are needed to explore the
effects of pulmonary rehabilitation programs for both sexes in the long-term.
Therefore, a follow-up study from the same cohort will be conducted including former
COVID-19 patients after six months of their rehabilitation stay.